NASHUA, N.H., Nov. 29, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new and real-world research demonstrating the value of ProFound AI® for Digital Breast Tomosynthesis (DBT) will be highlighted at the 107th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 28 – December 2. The Company is also showcasing its portfolio of world-class breast health solutions, including the latest versions of ProFound AI® Risk and PowerLook® Density Assessment, at McCormick Place in Chicago in the South Hall meeting suites 214-216.

"We are thrilled to have three important scientific presentations at RSNA this year, as these abstracts provide compelling new and real-world data regarding ProFound AI and the potential it offers to improve outcomes by supporting the earlier detection of breast cancer," said Stacey Stevens, President of iCAD, Inc. "Our efforts to empower clinicians with deep-learning technologies to optimize efficiency, confidence, and patient outcomes are demonstrated by the unrivaled specificity of our breast imaging AI solutions that are transforming breast cancer detection and risk-based personalized screening."

In a poster presentation titled "Use Of Artificial Intelligence Software To Identify Clinically Aggressive Lesions On Prior Digital Breast Tomosynthesis Exams Based On Molecular Subtypes," lead author Mary F. Ice, MD, radiologist at Rose Imaging Specialist and Solis Mammography, will discuss her research evaluating the use of ProFound AI in identifying and scoring lesions in prior DBT screening exams of cancer cases (session ID: SPR-BR-4).

Additionally, the following poster discussions will take place on Tuesday, November 30:

12:15 to 12:45 pm (session ID: BR03-A2):

"Effect Of Artificial Intelligence Software On Digital Breast Tomosynthesis Screening Cancer Detection And Abnormal Interpretation Rates Among Subspecialized Breast Radiologists: A Real-World Experience." Principal investigator Haley P. Letter, MD, Assistant Professor, Program Director of Breast Imaging and Intervention Fellowship and Associate Clerkship Director at University of Florida Health – Jacksonville, will present research from a real-world study assessing the impact of ProFound AI in DBT screening exams.

12:45 to 1:15 pm (session ID: BR03-B3):

"Tomosynthesis-driven AI-derived Breast Cancer Scoring Among A Racially Diverse Cohort Of Women Undergoing Screening: Potential For Triage And Precision Cancer Screening." Principal investigator Emily F. Conant, MD, professor and chief, Division of Breast Imaging at the Hospital of the University of Pennsylvania Medical Center, will discuss findings from an observational study evaluating ProFound AI and the impact of race on the software's performance and Case Scores.

Women's Health Homepage